Related to Intranasally Delivered Exosome-Encapsulated Drugs Shown to Treat Inflammatory Brain Disorders and Cancer in Mice

• Lipoxen Earns $2M from Baxter as Latter Selects PolyXen-Formulated FVIII Candidate
  
• RXi and EyeGate Join Forces for Noninvasive Ocular Delivery of RNAi Therapeutics
  
• NHLBI Ploughs $65M Follow-On Funding into Nanotech-Based Therapies and Diagnostics
  
• Phase III Trial Shows Near Equivalence of Baxter’s Subcutaneous IG Therapy to IV Product
  
• NeuroVive Taps to-BBB to Enhance Development of Its Stroke Treatment
  
• U.S. Team Implicates Newly Identified Gene in Ocular Melanoma Metastasis
  
• Markets Waver as BTG Announces £177M Cash and Shares Acquisition of Biocompatibles
  
• Team Generates 3-D Epithelial Tumors In Vitro from Normal Human Primary Cells
  
• New Role Revealed for Cancer-Promoting Gene AEG-1 in Chemoresistance
  
• MonoSol and Midatech Establish JV to Develop Transbuccal Nanoparticle Insulin Film
  
• Civitas Raises $20M for Parkinson Disease Program
  
• Adventrx Wraps Up $22.5M Registered Direct Offering
  
• Celsion to Obtain $5M in Financing and Fast-Track Milestone Payments from Japanese Partner
  
• Researchers Discover Over-Expression of DNA Sequences Called Satellite Repeats in Epithelial Cancers
  
• To-BBB Scores €4M to Advance Doxorubicin-Based Drug into the Clinic
  
• Enlyton to Develop ViroMed mAb for Cancer Detection and Drug Delivery
  
• OncoSec Nabs Inovio’s Electroporation IP for Delivery of Cancer Drugs
  
• Researchers Break Cancer Cells’ Mucus Barrier to Study Cytotoxic Therapies
  
• Extracellular Matrix Tugging Augments Cancer Metastasis
  
• FDA Filing for Tarsa’s Oral Calcitonin Projected by Year-End Following Positive Phase III Data